Hopital Beaujon

At Hopital Beaujon, investigators are evaluating new systemic and locoregional therapies for hepatocellular carcinoma, aiming to improve survival and disease control.

• Immune checkpoint inhibitor combinations
• Radioembolization with TheraSphere
• Targeted agents such as livmoniplimab and budigalimab
• Transarterial chemoembolization enhancements
• Biomarker-driven treatment strategies

With over 100 active trials and more than 460 investigators, the site focuses on translating innovative treatments into clinical benefit for liver cancer patients.

The department conducts studies on biliary tract cancers, including cholangiocarcinoma, to identify effective first‑line regimens and personalized approaches.

• Combination chemotherapy versus immunotherapy
• FGFR‑targeted agents for FGFR‑altered tumors
• IDH1‑mutant disease-specific trials
• Novel antibody‑drug conjugates
• Surgical adjuncts and peri‑operative strategies

Research integrates molecular profiling to match patients with targeted therapies, reflecting the site’s commitment to precision oncology.

Clinical programs address non‑alcoholic steatohepatitis and related metabolic dysfunction, testing agents that aim to resolve inflammation and fibrosis.

• Oral farnesoid X receptor agonists
• Fibrosis regression endpoints
• Biopsy‑confirmed cirrhosis cohorts
• Combination with lifestyle interventions
• Long‑term safety monitoring

These trials seek to halt disease progression and prevent transition to cirrhosis, supporting a growing need for effective NASH therapies.

Investigators evaluate novel immunomodulators for IgG4‑related disease, targeting disease flares and steroid‑sparing outcomes.

• Anti‑CD40 antibodies
• B‑cell depletion strategies
• Biomarker‑guided dosing
• Quality‑of‑life assessments
• Safety in multi‑organ involvement

The focus on IgG4‑RD reflects the site’s broader interest in immune‑mediated hepatic and systemic conditions.

A dedicated program investigates therapies for short bowel syndrome and intestinal failure, aiming to reduce dependence on parenteral nutrition.

• GLP‑2 analogues
• Nutrient absorption enhancement
• Long‑term safety in chronic use
• Patient‑reported outcome measures
• Combination with intestinal rehabilitation

These studies provide hope for improved nutrition and quality of life in patients with severe malabsorption.

The site runs trials on chronic hepatitis B, hepatitis D, and HIV co‑infection, assessing antiviral combinations and functional cure strategies.

• RNAi therapeutics
• Novel capsid inhibitors
• Combination with immune modulators
• Biomarker‑driven treatment cessation
• Safety in co‑infected populations

Efforts aim to achieve sustained viral suppression and reduce liver disease progression in high‑risk groups.

Research includes advanced therapies for Crohn’s disease and ulcerative colitis, focusing on maintenance of remission and postoperative outcomes.

• Selective IL‑23 inhibition
• Therapeutic drug monitoring strategies
• Post‑surgical recurrence prevention
• Microbiome‑based interventions
• Patient‑centred efficacy endpoints

Trials integrate endoscopic and clinical scores to optimize long‑term disease control.

Studies target gastro‑enteropancreatic neuroendocrine tumors, evaluating peptide receptor radionuclide therapy and emerging systemic agents.

• 177Lu‑edotreotide PRRT
• SSTR‑targeted radioisotopes
• Combination with checkpoint inhibitors
• Biomarker‑guided patient selection
• Quality‑of‑life outcomes

The program seeks to extend survival and improve symptom management for patients with metastatic NETs.